Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist II, Molecular Biology

Employer
Precision BioSciences, Inc.
Location
Durham, NC
Start date
Jul 31, 2022

View more

Job Details

Summary

 

As a member of the Core Technology Research and Development team the Scientist II will support cell and gene therapy programs. The incumbent will be involved in development of assays, discovery and development of antibodies or other proteins for cell therapy projects, development and/or characterization of nucleases for genome editing, genetic characterization of gene-edited cells.

 

**Please note, Precision BioSciences mandates COVID-19 vaccination of all employees. Accommodations may be made in accordance with applicable law.

 

Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position.  This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.

  • Development of assays
  • Generation of expression constructs
  • Phage display selection of antibodies or other proteins and their characterization
  • Optimization of selected proteins via affinity maturation and directed engineering
  • Rational protein engineering and characterization
  • Characterization of nucleases
  • Characterization of proteins by ELISA and functional assays
  • Genetic analysis of gene-edited cells
  • Assistance with any other related projects if needed

 

Qualifications

The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.

 

Required:

  • PhD in molecular biology, genetics, biochemistry, immunology, or related field, with 2+ years of experience, MS in molecular biology, genetics, biochemistry, immunology, or related field with 6+ years related academic or industry experience or equivalent combination of education and experience 
  • Strong molecular biology skills; experience with PCR amplification, quantitative PCR and/or digital PCR, cloning, genomic DNA manipulations/analysis, DNA sequencing analysis
  • Protein engineering and characterization experience, ELISA, small scale protein expression/purification
  • Ability to work independently and in team environment
  • Ability and desire to manage other researchers
  • Strong communication skills, including written and verbal reporting to supervisor, team, company, and at conferences

 

Preferred:

  • Practical knowledge of phage display or any other selection methods
  • Construction/cloning of combinatorial protein libraries
  • Antibody development/characterization
  • Experience in the development of T-cell therapies (such as CAR-T or TCR) or immunotherapies
  • Experience in the development of gene editing therapies

 

 

Travel Requirements

  • Minimal travel is expected for this position.
 

Location

  • This is an office-based position located at the main headquarters in downtown Durham, NC.

 

 

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs.  For additional information, please visit www. precisionbiosciences.com

 

Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

Company

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Company info
Website
Phone
919-314-5512
Location
302 East Pettigrew Street
Durham
North Carolina
27701
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert